GnRHa flare and IVF pregnancy rates
Authors:
- E. ConfinoECE. Confino
- X. ZhangXZX. Zhang
- R.R. KazerRKR.R. Kazer
- 4 November 2003
- journal article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 85 (1) , 36-39
Abstract
GnRH agonist administered early in the menstrual cycle (flare) causes an endogenous discharge of FSH and LH. Flare has been used in conjunction with gonadotropin ovarian stimulation for IVF 'poor responders'. There is an ongoing controversy regarding whether flare protocols improve pregnancy rates in 'poor responders'. The current study was designed to compare a GnRHa flare protocol with long suppression GnRHa IVF in 'poor responders'. Seventy-three newly diagnosed poor responders who failed long GnRHa suppression IVF attempts were compared retrospectively with 128 age-matched IVF patients previously known poor ovarian responders treated with a long GnRHa suppression protocol. 'Poor responders' consisted of patients with peak E(2) less than 1000 pg/ml and/or less than five mature follicles with diameter >15 mm on the day of hCG administration. Student's t-test was used to analyze the data and the chi-squared test was used to compare fertilization and pregnancy rates. The flare protocol produced higher peak E(2) levels (1647+/-747 vs. 720+/-258 mIU/ml, P0.05, NS). A comparison between the flare protocol group and the age-matched control group of poor ovarian responders subject to down regulation protocol, revealed higher peak E(2) levels and more mature follicles, respectively. However, both groups yielded comparable pregnancy rates. The use of high dose gonadotropin treatment in our study groups seems to be the only explanation for their subsequent successful outcome. We concluded that GnRH agonist flare protocol does not result in better IVF outcome compared with long GnRH agonist suppression protocol in IVF poor responders.Keywords
This publication has 13 references indexed in Scilit:
- In vitrofertilization following natural cycles in poor respondersGynecological Endocrinology, 2001
- A rational approach to the management of low responders in in-vitro fertilization: OpinionHuman Reproduction, 1999
- A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study groupHuman Reproduction, 1998
- Limited success using the “flare” protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilizationFertility and Sterility, 1997
- Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind studyHuman Reproduction, 1995
- Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized studyHuman Reproduction, 1993
- Comparison of ‘poor’ responders with ‘good’ responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilizationHuman Reproduction, 1991
- High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patientsFertility and Sterility, 1990
- Fertility prognosis in IVF treatment of patients with cancelled cyclesHuman Reproduction, 1989
- Outcome of in vitro fertilization in women with low response to ovarian stimulationFertility and Sterility, 1987